FDA Approves Releuko (filgrastim-ayow), a Biosimilar to Neupogen
February 28, 2022 -- The United States (U.S.) Food and Drug Administration (FDA) has approved Releuko (filgrastim-ayow), a biosimilar to Neupogen (filgrastim).
The FDA approval was based on a review of data that demonstrated a high degree of...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Drugs & Pharmacology | Filgrastim | Food and Drug Administration (FDA) | Neulasta | Neupogen | USA Health